Studies how removing part of the pancreas affects blood sugar in adults without diabetes
Observes blood sugar and metabolism after pancreas surgery in adults without diabetes.
Plain-language title generated from the registry record
Registry title: Clinical, Oncologic, and Metabolic Effects of Pancreatic Mass Loss After Pancreatectomy in Non-Diabetic Patients
Key facts
- Where
- Rome, ItalySee the site
Where in Italy
- Fondazione Policlinico Universitario Agostino Gemelli IRCCSRome, ItalyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
- Trial code
- NCT07608055
- Record updated
- 3 September 2026
- Original description
This study will examine how removal of part or all of the pancreas affects blood sugar control, metabolism, and clinical outcomes over time.Read full original descriptionShow less
Clinical, Oncologic, and Metabolic Effects of Pancreatic Mass Loss Following Partial, Near-Total, and Total Pancreatectomy in Patients Without Diabetes at Baseline: A Monocentric Ambispective Observational Study
This study will examine how removal of part or all of the pancreas affects blood sugar control, metabolism, and clinical outcomes over time.
The study will include adults without diabetes before surgery who undergo pancreatic surgery as part of routine clinical care at Fondazione Policlinico Universitario A. Gemelli IRCCS.
Researchers will study whether participants develop diabetes after surgery and whether this risk changes according to the type of pancreatic resection.
Information from routine clinical care, metabolic tests, imaging, and pancreatic tissue samples collected during surgery may be used for research analyses.
Inclusion: Adult patients (≥18 years); No diabetes mellitus at baseline; Undergoing partial, near-total, or total pancreatectomy at the study center; Availability of clinical and metabolic data according to study component; Written informed consent for the prospective component.
Exclusion: Diabetes mellitus at baseline; Age <18 years; Missing key clinical data precluding eligibility assessment or primary outcome evaluation; Refusal or inability to provide informed consent for the prospective component, where applicable.